Matthew Fenn, Head of Business Development, and Clair Brooks, Applications Specialist, sat down with ONdrugDelivery to discuss the motivation for adopting more clinically representative test set-ups in orally inhaled and nasal drug product development particularly for demonstrating bioequivalence. They also delved into the practicalities of doing so and the tools available to support such efforts.
This article is taken from from ONdrugDelivery April 2024, Pulmonary & Nasal Drug Delivery, Issue 158, pages 36-41. © 2024 Frederick Furness Publishing.
